Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in oncology stocks.
1 - 6 of 6
*Signup bonus information updated weekly.
Take a deeper dive into oncology stocks
If you're interested in investing in the cancer industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.
1. Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
Amgen stock opened the day at $271.73 after a previous close of $269.04. The latest price was $268.98 (25-minute delay). Amgen is listed on the NASDAQ, has a trailing 12-month revenue of around USD26.6 billion and employs 25,200 staff.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company stock opened the day at $58.58 after a previous close of $58.54. The latest price was $57.89 (25-minute delay). Bristol-Myers Squibb Company is listed on the NYSE, has a trailing 12-month revenue of around USD$45.2 billion and employs 34,300 staff.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.
Five Prime Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.2 million and employs 51 staff.
Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
Gilead Sciences stock opened the day at $75.67 after a previous close of $75.53. The latest price was $75.55 (25-minute delay). Gilead Sciences is listed on the NASDAQ, has a trailing 12-month revenue of around USD$27.4 billion and employs 17,000 staff.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians.
Novartis AG ADR stock opened the day at $101.29 after a previous close of $101.42. The latest price was $100.26 (25-minute delay). Novartis AG ADR is listed on the NYSE, has a trailing 12-month revenue of around USD$53.1 billion and employs 103,000 staff.
Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Cardiff Oncology stock opened the day at $7.78 after a previous close of $7.66. The latest price was $7.87 (25-minute delay). Cardiff Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$412,000 and employs 25 staff.
Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8.
Surface Oncology stock opened the day at $7.14 after a previous close of $7.12. The latest price was $7.12 (25-minute delay). Surface Oncology is listed on the NASDAQ and employs 35 staff.
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc.
Trillium Therapeutics stock opened the day at $8.67 after a previous close of $8.63. The latest price was $8.50 (25-minute delay). Trillium Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$43,000 and employs 33 staff.
Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.
Mersana Therapeutics stock opened the day at $1.27 after a previous close of $1.25. The latest price was $1.25 (25-minute delay). Mersana Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$38.7 million and employs 228 staff.
Sign up with an online broker or platform to invest in one or more of these oncology stocks.
Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
Search for the stock you're interested in. Find the stock by name or ticker symbol, like AMGN or BMY.
Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
Choose an order type. Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the cancer industry, track how your stock performs to decide when it’s time to sell.
While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
How likely would you be to recommend finder to a friend or colleague?
Very UnlikelyExtremely Likely
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.